



# Supporting Information

Russi et al. 10.1073/pnas.1710401115




**Fig. S1.** ILC2 identification by flow cytometry. (A) Representative gating scheme for identification of ILC2s (CD45<sup>+/hi</sup>Lin<sup>-</sup>IL-7R $\alpha$ <sup>+</sup>ST2<sup>+</sup>) in the CNS. (B) Expression of additional canonical ILC2 markers CD25, VLA-4, and c-kit by ILC2s in the CNS.



**Fig. S2.** ILC2s derived from female and male SJL mice show similar responses to ILC2-activating factors. (A) ILC2 precursors (ILC2Ps:  $CD45^+Lin^- \alpha_4\beta_7^+CD25^+$ ) in the bone marrow of naïve mice. Numbers in flow cytometry plots represent percentage of  $CD45^+Lin^- \alpha_4\beta_7^+CD25^+$  cells of total cells. (B) Percentage of thymic ILC2Ps ( $Lin^-CD4^-CD8^-CD44^+c-kit^+CD25^+$ ) in naïve mice. Data from individual mice is graphed and expressed as the percentage  $CD45^+Lin^- \alpha_4\beta_7^+CD25^+$  cells of total cells. (C–F) Quantification of mature ILC2s ( $CD45^{+hi}Lin^-IL-7R\alpha^+ST2^+$ ) in the indicated tissues of naïve mice. Numbers in flow cytometry plots represent the percentage of  $IL-7R\alpha^+ST2^+$  cells of the  $CD45^+Lin^-$  population. Data from individual mice is graphed and expressed as the percentage of the  $CD45^+$  population. (G–J) ILC2s ( $CD45^{+hi}Lin^-IL-7R\alpha^+ST2^+$ ) in the indicated tissues after three consecutive daily doses of 300 ng IL-33. Numbers in flow cytometry plots represent the percentage of the  $CD45^{+hi}Lin^-$  population. Data from individual mice is graphed and expressed as the percentage of  $CD45^+$  population. Representative flow plots are shown. Gating is based on FMO controls. ns:  $P > 0.05$  by Student's *t* test.





**Fig. S5.** BMMC viability in the presence of flutamide and its solvent. The percentage of live BMBCs identified by Trypan blue negativity after stimulation under the indicated conditions for 6 h. Flutamide was dissolved in a 1:1,000 solution of ethanol (EtOH).